Use of Selective Alternative Therapies for Treatment of OCD

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2023 Apr 12

PMID 37041856

Authors

Iman Khan

Taimoor Asif Jaura

Alaa Tukruna

Aabiya Arif

Sameer Saleem Tebha

Sameen Nasir

Dattatreya Mukherjee

Nadia Masroor

Abubakr Yosufi

Affiliations

Soon will be listed here.

Abstract

About 40% of the people with the obsessive-compulsive-disorder do not experience the desired outcome after the existing treatment, and its several side effects were reported. This systematic review was conducted to evaluate the efficacy and tolerability of alternative drugs and assess the possibility of their use as treatment options for obsessive-compulsive-disorder. The Scientific databases PubMed, Science Direct, Google Scholar, Cochrane, Directory of Open Access Journals, MedRxiv and BioRxiv, were searched from inception to March 2022, using appropriate search strategies for each drug and following the Prisma guidelines 2020. Studies were selected according to the already set criteria and assessed for bias. Data were extracted, and descriptive and continuous data were analyzed and presented as frequency/percentage and mean. A total of 16 observational and interventional studies were included for data extraction. The studies focused on four drugs, Psilocybin (n=4), Cannabis (n=7), Nicotine (n=3), and Morphine (n=2), that were used to test out their effect on OCD symptoms. Overall, the majority of the studies showed promising results by documenting a reduction in Y-BOCS scores. However, few subjects, specifically those using nicotine or Cannabis, did not affect their condition or self-reported worsening symptoms. Few side effects were also noticed. This systematic review found that the drugs mostly showed a positive response. All Psilocybin and morphine users, 88.2% and 74.1% of the nicotine and Cannabis users, respectively, reported experiencing the positive effect of these drugs, indicating that these drugs have the potential to be used in the management of OCD. However, further research is required in this arena to thoroughly understand the mechanism of action by which these drugs produce their therapeutic effect. Policies to destigmatize and encourage clinical trials with these drugs are crucial for exploring the use of these drugs as a treatment option for OCD.

Citing Articles

Psychedelics for the Treatment of Obsessive-Compulsive Disorder: Efficacy and Proposed Mechanisms.

Collins H Int J Neuropsychopharmacol. 2024; 27(12).

PMID: 39611453 PMC: 11635828. DOI: 10.1093/ijnp/pyae057.

Psilocybin in pharmacotherapy of obsessive-compulsive disorder.

Owe-Larsson M, Kaminska K, Buchalska B, Mirowska-Guzel D, Cudnoch-Jedrzejewska A Pharmacol Rep. 2024; 76(5):911-925.

PMID: 39088105 PMC: 11387457. DOI: 10.1007/s43440-024-00633-1.

References

Barik J, Wonnacott S . Molecular and cellular mechanisms of action of nicotine in the CNS. Handb Exp Pharmacol. 2009; (192):173-207. DOI: 10.1007/978-3-540-69248-5_7. View

Glare P, Walsh D, Sheehan D . The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care. 2006; 23(3):229-35. DOI: 10.1177/1049909106289068. View

Salin-Pascual R, Basanez-Villa E . Changes in compulsion and anxiety symptoms with nicotine transdermal patches in non-smoking obsessive-compulsive disorder patients. Rev Invest Clin. 2004; 55(6):650-4. View

Lundberg S, Carlsson A, Norfeldt P, Carlsson M . Nicotine treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28(7):1195-9. DOI: 10.1016/j.pnpbp.2004.06.014. View

Kayser R, Haney M, Raskin M, Arout C, Simpson H . Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study. Depress Anxiety. 2020; 37(8):801-811. PMC: 7423713. DOI: 10.1002/da.23032. View

Matsushima Y, Shirota O, Kikura-Hanajiri R, Goda Y, Eguchi F . Effects of Psilocybe argentipes on marble-burying behavior in mice. Biosci Biotechnol Biochem. 2009; 73(8):1866-8. DOI: 10.1271/bbb.90095. View

Aouizerate B, Guehl D, Cuny E, Rougier A, Bioulac B, Tignol J . Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. Prog Neurobiol. 2004; 72(3):195-221. DOI: 10.1016/j.pneurobio.2004.02.004. View

Benowitz N . Nicotine addiction. Prim Care. 1999; 26(3):611-31. DOI: 10.1016/s0095-4543(05)70120-2. View

Motaghinejad M, Fatima S, Banifazl S, Bangash M, Karimian M . Study of the effects of controlled morphine administration for treatment of anxiety, depression and cognition impairment in morphine-addicted rats. Adv Biomed Res. 2016; 5:178. PMC: 5156972. DOI: 10.4103/2277-9175.188491. View

10.

Koran L, Aboujaoude E, Bullock K, Franz B, Gamel N, Elliott M . Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005; 66(3):353-9. DOI: 10.4088/jcp.v66n0312. View

11.

Spradlin A, Mauzay D, Cuttler C . Symptoms of obsessive-compulsive disorder predict cannabis misuse. Addict Behav. 2017; 72:159-164. DOI: 10.1016/j.addbeh.2017.03.023. View

12.

Doshi P . Surgical treatment of obsessive compulsive disorders: Current status. Indian J Psychiatry. 2009; 51(3):216-21. PMC: 2772224. DOI: 10.4103/0019-5545.55095. View

13.

Van Ameringen M, Patterson B, Simpson W . DSM-5 obsessive-compulsive and related disorders: clinical implications of new criteria. Depress Anxiety. 2014; 31(6):487-93. DOI: 10.1002/da.22259. View

14.

Cho Y, Ernst M, Fudge J . Cortico-amygdala-striatal circuits are organized as hierarchical subsystems through the primate amygdala. J Neurosci. 2013; 33(35):14017-30. PMC: 3756751. DOI: 10.1523/JNEUROSCI.0170-13.2013. View

15.

Richter P, Ramos R . Obsessive-Compulsive Disorder. Continuum (Minneap Minn). 2018; 24:828-844. DOI: 10.1212/CON.0000000000000603. View

16.

Pasquini M, Garavini A, Biondi M . Nicotine augmentation for refractory obsessive-compulsive disorder. A case report. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 29(1):157-9. DOI: 10.1016/j.pnpbp.2004.08.011. View

17.

Johnson M, Garcia-Romeu A, Cosimano M, Griffiths R . Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014; 28(11):983-92. PMC: 4286320. DOI: 10.1177/0269881114548296. View

18.

Mauzay D, LaFrance E, Cuttler C . Acute Effects of Cannabis on Symptoms of Obsessive-Compulsive Disorder. J Affect Disord. 2020; 279:158-163. DOI: 10.1016/j.jad.2020.09.124. View

19.

Bryant R, Creamer M, ODonnell M, Silove D, McFarlane A . A study of the protective function of acute morphine administration on subsequent posttraumatic stress disorder. Biol Psychiatry. 2008; 65(5):438-40. DOI: 10.1016/j.biopsych.2008.10.032. View

20.

Grimm O, Kraehenmann R, Preller K, Seifritz E, Vollenweider F . Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. Eur Neuropsychopharmacol. 2018; 28(6):691-700. DOI: 10.1016/j.euroneuro.2018.03.016. View